Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28286570 | 0.80 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL4080725 | 0.80 | RNPEP (0.34) | ALDH1A1 | |
| SCHEMBL4080730 | 0.80 | RNPEP (0.34) | ALDH1A1 | |
| SCHEMBL137240 | 0.78 | RNPEP (0.33) | ALDH1A1 | |
| SCHEMBL4478265 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL8631296 | 0.68 | RNPEP (0.35) | ALDH1A1 | |
| SCHEMBL31512988 | 0.68 | CA4 (0.41) | — | |
| SCHEMBL29013093 | 0.68 | RNPEP (0.35) | ALDH1A1 | |
| SCHEMBL11192504 | 0.67 | NOS1 (0.33) | ALDH1A1 | |
| SCHEMBL162368 | 0.67 | GGT1 (0.52) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11083685-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-10398640-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. | 2019-09-03 | — | — | US | disclosed |
| EP-2525774-B1 | NEW LIPO-PHOSPHATED OR LIPO-SULPHATED COMPOUND, COMPOSITIONS COMPRISING IT AND TOPICAL USES THEREOF | SEDERMA SA (FR) | 2016-03-30 | — | — | EP | disclosed |
| US-20160058816-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058693-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-9180157-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. | 2015-11-10 | — | — | US | disclosed |
| US-9180158-B2 | Methods for treating scars and aging skin | ALLERGAN, INC. | 2015-11-10 | — | — | US | disclosed |
| US-20130337088-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN, INC. | 2013-12-19 | — | — | US | disclosed |
| US-8603498-B2 | Lipo-phosphated or lipo-sulphated compound, compositions comprising it and topical uses thereof | SEDERMA, S.A.S. (FR) | 2013-12-10 | — | — | US | disclosed |
| US-8591961-B2 | Aesthetic treatment of scars and aging skin | ALLERGAN, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20130004439-A1 | Lipo-Phosphated or Lipo-Sulphated Compound, Compositions Comprising It and Topical Uses Thereof | SEDERMA, S.A.S. (FR) | 2013-01-03 | — | — | US | disclosed |
| US-20120058167-A1 | METHODS FOR TREATING SCARS AND AGING SKIN | ALLERGAN, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120058076-A1 | AESTHETIC TREATMENT OF SCARS AND AGING SKIN | ALLERGAN, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2011086532-A1 | NEW LIPO-PHOSPHATED OR LIPO-SULPHATED COMPOUND, COMPOSITIONS COMPRISING IT AND TOPICAL USES THEREOF | SEDERMA (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130004439-A1 | Lipo-Phosphated or Lipo-Sulphated Compound, Compositions Comprising It and Topical Uses Thereof | LOXL3, CUTA, LOXL4 | ALDH1A1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.